BioTrends Research Group, one of the world's leading research and
advisory firms for specialized biopharmaceutical issues, finds that
analysis of U.S. longitudinal patient-level claims data reveals the use
of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly
diagnosed schizophrenia patients continues to grow. With this increase,
Abilify has the second-highest first-line patient share of newly
diagnosed patients among atypical antipsychotics. According to Treatment
Algorithms in Schizophrenia, oral risperidone (Janssen's
Risperdal, generics) continues to capture the greatest share of newly
diagnosed schizophrenia patients among atypical antipsychotics, due to
its availability as a generic. Atypical antipsychotics are the
cornerstone treatment for schizophrenia and earn the largest percentage
of patient share compared with other drug classes in the treatment of
newly diagnosed patients.
"Abilify has a more favorable tolerability profile, with a lower risk of
metabolic side effects compared with other atypicals such as Eli Lilly's
Zyprexa, and has shown efficacy in reducing the symptoms of depression;
both factors may be reasons why physicians are turning to Abilify
earlier in the treatment algorithm," said Director Nicole Westphal, Ph.D.
BioTrends' analysis also explores treatment patterns for recently
treated schizophrenia patients, which captures patients treated in the
third quarter of 2011 and reviews therapies in their treatment history.
Among recently treated patients who switch to Abilify, 17.5 percent of
patients progress from risperidone. Because of Abilify's favorable
side-effect profile, patients switching to Abilify may have exhibited
tolerability issues with risperidone, particularly weight gain,
hyperlipidemia and metabolic side effects.